Join over 25,000 investors, academics and operators who receive the latest news on the psychedelic science and healthcare industry. Straight to your inbox once a week.
Mapping the effects of ketamine on the brain, Psilocybin analogue shows positive results, Psychedelic therapy programmes launch for burnout and heartbreak.
Short Wave Pharma aims to innovate eating disorder care, Volunteers called to support groundbreaking psychedelic research, Microdosing could help people with ADHD.
How to regulate psychedelics for non-medical use, Groundbreaking trial to assess real-world efficacy of MDMA therapy for PTSD, Canada recommends launch of psychedelic research programme for Veterans.
Integrating metaphysics into psychedelic therapy, establishing a psilocybin microdosing regimen, the risk of chronic psychedelic and MDMA microdosing for valvular heart disease.
Improved efficacy of DMT therapy with SSRIs, Transcend Therapeutics announces the receipt of a $1 million grant with Yale University, Canada approves the first legal medical psilocybin access.
FDA-approval of MDMA therapy on the horizon for 2024, Psilocybin use in naturalistic settings produces lasting results, Psychedelics supported mental health during COVID-19.
Join over 25,000 investors, academics and operators who receive the latest news on the psychedelic science and healthcare industry. Straight to your inbox once a week.
Subscribe to the Psychedelics Newsletter
Join over 25,000 investors, academics and operators who receive the latest news on the psychedelic science and healthcare industry. Straight to your inbox once a week.